Effect of applied energy in renal sympathetic denervation with magnetic resonance guided focused ultrasound in a porcine model
© The Author(s). 2017
Received: 3 December 2016
Accepted: 27 March 2017
Published: 12 June 2017
Past catheter-based and focused ultrasound renal denervation studies have indicated that procedure efficacy is related to the number of ablations performed or the amount of energy used for the ablation. This study extends those prior results and investigates energy level effects on the efficacy of MR guided focused ultrasound renal denervation performed in a porcine model.
Twenty-four normotensive pigs underwent unilateral denervation at three intensity levels. The applied intensity level was retrospectively de-rated to account for variability in animal size. Efficacy was assessed through evaluating the norepinephrine present in the kidney medulla and through histological analysis. The treatment was performed under MRI guidance including pre- and post-procedure T1-weighted and quantitative T1 and T2 imaging. During treatment, the temperature in the near field of the ultrasound beam was monitored in real time with MR temperature imaging. Energy delivery in the regions surrounding the renal artery was independently confirmed through an invasive fiberoptic temperature probe placed in the right renal artery.
Animals that underwent denervation at a de-rated acoustic intensity of greater than 1.2 kW/cm2 had a significantly lower norepinephrine concentration in the kidney indicating successful denervation. Images obtained during the treatment indicated no tissue changes in the kidneys as a function of the procedure but there were significant T1 changes present in the right lumbar muscles, although only one animal had indication of muscle damage at the time of necropsy.
While MR guided focused ultrasound renal denervation was found to be safe and effective in this normotensive animal model, the results indicated the need to incorporate patient-specific details in the treatment planning of MRgFUS renal denervation procedure.
KeywordsFocused ultrasound High intensity focused ultrasound Renal denervation Hypertension
Hypertension represents a critical health challenge for millions of people throughout the world . Since increased age and obesity are two of the most significant risk factors for hypertension, these numbers are expected to drastically increase  making the treatment of hypertension a significant public health issue. While uncontrolled hypertension in many patients is due to lack of adherence to the physician prescribed treatment, or inadequate treatment [3, 4], approximately 10% of the patient population who are currently taking three or more medications continue to have persistent high blood pressure and are identified with resistant hypertension .
Renal sympathetic nerves play a key role in initiating and maintaining systemic hypertension [6–8] and regulate several renal functions that are believed to contribute to hypertension . Indeed, before effective pharmaceutical treatments were available, the surgical removal of these nerves was used as a treatment for hypertension . The high morbidity rates of this surgical intervention led to the investigation and development of less invasive techniques including catheter-based techniques.
Recently, a radiofrequency (RF) catheter-based technique has been used to ablate the sympathetic nerves through the lumen of the main renal artery [11, 12]. While early feasibility trials showed very promising results including significant reductions in blood pressure , reduction of the left ventricle mass index , improved insulin sensitivity and glucose metabolism  and reduction of atrial fibrillation recurrences when used as a combination therapy , recent results have been more variable. The large, randomized Symplicity HTN-3 trial did not show a significant decrease in blood pressure when compared to the sham-control group . There are several factors that could explain the lack of efficacy within the Symplicity HTN-3 clinical trial . Approximately 40% of patients had their medications altered during the 6-month post ablation observation period and there was variability in the experience levels of the treating physicians. Both of these experimental design variables increased the probability of confounding variables . Importantly, not every patient received the same number of ablation points, with subsequent data analysis suggesting that patients receiving more ablations had greater reductions in blood pressure compared with either the sham group or with patients that received fewer ablations . This result indicates a potential dose effect in renal denervation procedures.
Both pre-clinical and clinical studies have demonstrated the feasibility of using focused ultrasound (FUS) as a non-invasive ablation technique to achieve renal denervation. In Wang et al. , healthy canines underwent bilateral renal denervation using extracorporeal FUS with ultrasound color Doppler flow imaging for targeting. When compared to the sham procedure group, a significant decrease in blood pressure (−12.3/−15.9 mmHg) and plasma noradrenaline concentration (−50.1%) were detected 6 days post-procedure. Kona Medical Company has completed two clinical trials (WAVE I  and WAVE II ) using ultrasound imaging guidance that resulted in significant 6-month blood pressure reductions (WAVE I [N = 24]: −29/−12 mmHg, WAVE II [N = 17]: −19.4/−6.5 mmHg).
Two studies have investigated performing renal denervation with MRI guided FUS (MRgFUS) in a normotensive porcine model [23, 24]. In both MRgFUS feasibility studies [23, 24], the safety of the procedure was confirmed by lack of tissue damage in the renal arterial walls as well as the skin and other intervening tissues. In , renal denervation was performed unilaterally in ten pigs using MRgFUS. There was a reduced kidney norepinephrine concentration in the treated kidney compared to the untreated kidney in seven of the ten animals, but no corresponding decrease in blood pressure. A signal increase in T2-weighted images indicated an increase in edema and potential damage in the treated area. In a separate study , a similar unilateral treatment was performed on five pigs and both safety and efficacy were assessed. A significant reduction of nerve cross-sectional area was observed as well as a reduction of kidney tissue norepinephrine concentration, ranging from a 10 to 65% decrease, indicating successful renal denervation was performed . Similar to the Symplicity HTN-3 trial results, there was a positive correlation between the amount of energy applied and the reduction in kidney norepinephrine levels.
This study further investigates the potential energy level effect of renal denervation in a normotensive porcine model that has been observed in prior studies. Both the safety of the MRgFUS renal denervation procedure and the efficacy of the renal denervation procedure are reported and analyzed.
This study was conducted with Institutional Animal Care and Use Committee approval under Good Laboratory Practices standards. Twenty-four animals (Yorkshire pigs; female; 40–50 kg) underwent unilateral renal denervation in the study. Anesthesia was induced with a Telazol, Ketamine and Xylazine cocktail (4.4, 2.2, 2.2 mg/kg respectively) administered through an intramuscular injection and maintained throughout all procedures using inhaled isoflurane (1–3%, inhaled). All hair in the intended acoustic window on the back of the animal was removed using clippers and a depilatory cream. In order to obtain an independent confirmation of energy delivery at the treatment site, a fiber optic temperature probe (Neoptix, Quebec, Canada) was placed in the right renal artery under fluoroscopic guidance through percutaneous access of the femoral artery . The fiberoptic temperature probe tip was placed approximately at the bifurcation junction before entry into the kidney.
MRgHIFU renal sympathetic denervation procedure
Six study groups that underwent unilateral renal denervation with MRgFUS
Typical scan parameters for all MRI sequences used in the study
# of slices
3D T1w Vibe
154 × 320
1.7 × 1.2 × 3
202 × 256
1.4 × 1.3 × 4
124 × 192
2.2 × 1.8 × 5
126 × 192
2.2 × 1.8 × 5
3D segmented-EPI, MRTI
96 × 128
2 × 2 × 3
All animals received approximately 20 individual sonications in the regions immediately surrounding the right renal artery (±5 mm) using the acoustic intensity indicated in Table 1. Because imaging artifacts due to the presence of motion (e.g. blood flow, peristalsis, respiration) and fat render MR temperature imaging (MRTI) techniques inaccurate in the regions directly surrounding the renal artery, MRTI measurements were not obtained in the treatment region. However, MRTI was performed in the near-field regions surrounding the spine during all MRgFUS sonications in real time using a 3D segmented Echo Planar Imaging (EPI) sequence (parameters detailed in Table 2). The temperature measurements obtained from the fiber optic probe placed in the right renal artery were also recorded continuously throughout the denervation procedure. The mean electric power output was recorded for every sonication; acoustic power output was later determined using force-balance measurements obtained outside the MRI . After the renal denervation procedure, the pre-treatment imaging protocol was repeated. In addition, post-contrast 3D T1w VIBE scans were performed after injection of contrast agent (0.1 mmol/kg of MultiHance, Bracco Diagnostics Inc., Princeton, NJ) to evaluate the tissues surrounding the treatment region.
Tissue harvest and preparation
At the time of harvest the renal artery, kidneys, and underlying muscle were examined bilaterally for any gross abnormalities. Subsequently, the kidneys were removed, and a segment of the medulla was dissected and frozen immediately on dried ice. This tissue was used to evaluate levels of norepinephrine (see methods below). The renal artery and surrounding tissue were harvested and fixed in formalin for a minimum of 24 h. Post fixation, the length of the left and right arteries were measured and then each artery divided into five equal segments. Region 1 was designated as the region closest to the aorta and region 5 closest to the kidney as indicated in Fig. 1. The segments were dehydrated in increasing concentrations of alcohol, embedded in paraffin, sectioned (5 μm), and then stained with haematoxylin and eosin (H&E) or Masson’s Trichrome Stain.
MRI data analysis
One H&E section from each renal artery region was histomorphometrically evaluated via light microscopy. In addition, H&E stained slides were digitally scanned using a ScanScope® AT2 system. The ImageScope software in eSlideManager (Aperio/Leica Biosystems, Vista, CA) was used to visualize each slide [23, 29]. Quantitative measurement tools including positive pixel count algorithms within the ImageScope software were used to determine the number of nerves, nerve cross-sectional area, arterial area, and the distance between the arterial lumen and the nerve. For calculation and analysis of mean nerve area, only nerves with an area greater than 5000 μm2 and smaller than 70,000 μm2 were included in the calculation. Nerve area reduction results are presented as a ratio of the summation of the treated to control sides for each animal (Area ratio = Area treated /Area control ).
A pathologist blinded to the group assignments evaluated the H&E and Masson’s trichrome stained histological sections to determine if there was any evidence of nerve or arterial damage in the form of necrosis, inflammation, fibrosis, hyperplasia, or structural abnormalities. Arterial wall was evaluated for evidence of fibrinoid necrosis, concentric thickening, attenuation, hyalinizaytion, edema, inflammation or collagen deposition. In addition, for each artery lining endothelium was evaluated for evidence of sloughing, necrosis, hyperplasia or evidence of thickening in basement membrane. Nerve tissue was evaluated for evidence of traumatic or degenerative changes.
At the time of analysis the frozen kidney sections prepared during the necropsy were thawed, weighed, and then homogenized in ice cold 0.8 M EDTA (Ethylenediaminetetraacetic acid). The concentration of norepinephrine within the homogenate was determined with an enzyme-linked immunosorbent assay (ELISA) following the manufacturers instructions (Rocky Mountain Diagnositcs, Colorado Springs, CO). Norepinephrine results are presented as a ratio of the concentration measured in the treated to the control kidney (NE ratio = NE treated /NE control ).
Power adjusted analysis
Summary of study parameters. Time to Evaluation (TTE) was either 9 days (9d) or 6 months (6 m)
Acoustic Power (W)
Mean propagation path length, z (cm)
Derated Intensity, I D (kW/cm2)
Medulla norepinephrine (ng/mL/g)
Spinous process enhancement (mm)
To determine if there was a differential response between the low and high rated energy groups, kidney norepinephrine and nerve area ratios were compared with a t-test (JMP Pro 11; SAS; Cary, NC) with significance set at p < 0.05.
After sacrifice, the excised renal artery was measured and then divided into five approximately equal segments. The length of the renal artery on the treated side was statistically longer than the control side at 9 days (treated: 30.4 ± 4.6 mm vs. control: 33.4 ± 5.6 mm, p < 0.01) but not at 6 months (treated: 33.4 ± 5.6 mm vs. control 29.6 ± 4.0 mm, p = 0.13). There was no difference in renal artery area between the treated and control sides at either the 9 day (treated: 4.2 ± 1.9 mm2, control: 4.1 ± 1.7 mm2, p = 0.96) or 6 month (treated: 8.8 ± 2.4 mm2, control: 7.9 ± 1.9 mm2, p = 0.45) study endpoint. In terms of nerve histology, 82% of the nerves on the treated side and 79% of the nerves on the control side were located within less than 3 mm of the lumen of the artery. Additionally, 68% of the nerves on the treated side and 71% of the nerves on the control side were located between Regions 3–5 (Fig. 1), closer to the renal pelvis.
One animal (animal ID 8, study group 3) did have muscle damage present at the time of necropsy as shown in Fig. 7(e). This was predominantly composed of chronic lymphocytic infiltrate of the muscle tissue. Histopathologic review indicated no evidence of tissue damage involving artery wall endothelium, artery wall, or nerve tissue of any of the animals tested. In addition there was no difference observed between control groups at 9 days, or 6 month in comparison to their corresponding time point treated animals either in the high or low adjusted intensity animal groups.
This study complements previous work that indicated RF catheter and focused ultrasound renal denervation procedures are more efficacious with increased energy deposition  or number of ablations . While this MRgFUS renal denervation study evaluated three distinct applied acoustic intensities, a retrospective analysis scheme was employed to take into account the inter-animal variance of the distance between the skin and target region (6.3 to 9.5 cm). A de-rated acoustic intensity metric was computed for each animal by simplifying the heterogeneity of the animal anatomy to a homogeneous medium with an assumed attenuation value of muscle. When the animals were regrouped using this metric, it was found that animals with a de-rated acoustic intensity of ≥ 1.2 kW/cm2 had a significantly lower kidney medulla norepinephrine ratio (NE ratio ), reduced by approximately 54%, 9 days after the renal denervation procedure. Since kidney medulla norepinephrine is a proven robust marker for effective renal nerve destruction , this significant decrease further confirms that increased energy deposition leads to more efficacious outcomes. However, unlike a previous study , a reduction of nerve cross-sectional area was not observed in this study. In addition, there was not a consistent demonstration of nerve damage as measured through histologic analysis. Therefore, while there was a significant decrease in NE seen in the higher de-rated acoustic intensity group, this efficacy was not confirmed by a secondary metric.
The retrospective de-rated acoustic intensity metric used in this study also highlights the need to incorporate patient-specific details when developing a treatment plan for renal denervation FUS procedures. Due to the difficulty of obtaining MR temperature imaging data at the treatment region immediately surrounding the renal arteries, it is difficult to calibrate applied power in situ with a test sonication as is done in other clinical MRgFUS procedures . Freyhardt et al.  did have a calibration step in their porcine renal denervation study. Test sonications were performed in the ipsilateral longissimus lumborum muscle, posterior to the target site. However, the energy was determined based on a uterine fibroid protocol and was not tailored specifically to renal denervation. The use of a subject-specific derating metric that took into account the heterogeneity of each subject would potentially increase the efficacy of the denervation procedure.
As demonstrated by the excessive near-field heating in animal 8, the incorporation of additional patient-specific details for renal denervation treatments must include the presence of bone and bowel in the acoustic window. This has been shown in other MRgFUS clinical applications such as uterine fibroid treatments where segments of bowel anterior to the target area can adversely affect the MRgFUS treatment . The gas present in the bowel causes the ultrasound energy to be reflected towards the skin causing unwanted heating away from the intended target. While techniques can be employed to mitigate these effects, such as rectal filling, these techniques were not used in this study.
It has been demonstrated that phase aberration can affect the efficiency of an ultrasound treatment not only in transcranial applications  but also in soft tissue anatomies, such as the breast [34, 35]. For renal denervation applications, the presence of the spine as well as multiple tissue types in the acoustic window (including muscle, fat, kidney and liver) can potentially distort the ultrasound beam’s focus and reduce the energy delivered to the treatment region. The variability of the temperature rise measured with the intravascular fiberoptic temperature probe as a function of de-rated power could be due to the presence of phase aberrations. While not included in this work, this hypothesis is currently being further evaluated by a study that is retrospectively simulating all the renal denervation treatments in this work by creating segmented models incorporating all tissue types and performing ultrasound simulations.
In this study, approximately 70% of the nerves were located in regions 3 through 5 of the renal artery, meaning most nerves were located within 15 to 19 mm of the renal pelvis. This spatial distribution agrees with the finding of a previous study . An advantage of MRgFUS over catheter-based renal denervation techniques is MRgFUS can be applied independent of vascular structure. In this study, the regions surrounding the renal pelvis were easily targeted. Although nearly the entire kidney was in the near field of the acoustic window, there was no damage detected in the kidney tissue at necropsy. In addition, the T1- and T2-maps measured no acute tissue changes in the kidney as a result of the renal denervation procedure.
While performing unilateral denervation allowed each animal to serve as its own control, the achievable reduction in NE ratio may be limited in this study compared to a bilateral denervation protocol. Bilateral denervation was not possible in this study because of the amount of gas present in the bowel and the prominent spinal transverse process, which limited the acoustic window accessible by the transducer to the right side of the animal. A different transducer design or other hardware modifications may have been able to access the left renal artery making bilateral denervation possible.
This study demonstrates an increased efficacy effect in renal denervation using MRgFUS when higher in situ acoustic intensity levels are applied, as measured by a reduction in norepinephrine in groups treated at the higher acoustic intensity levels. The quantitative measurement of both T1- and T2-maps before and after the renal denervation treatment demonstrated that there was no acute injury in the kidneys, but edema was present in the muscle tissue in 63% of the animals (88% of the animals in which the T1 and T2 measurements were successfully acquired). These results indicate the need to incorporate patient-specific details in the treatment planning of MRgFUS renal denervation treatments to ensure both the safety and efficacy of the procedure.
We acknowledge the contributions of Jesse Crowne, Dennis Parker, Robb Merrill and Alexis Farrer to this study.
This work was funded by the Joe W. and Dorothy Dorsett Brown Foundation.
Availability of data and materials
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
JS, AP and HB performed tissue harvest and analysis. JS and HB performed all norepinephrine analysis. JdB, JRH, EM and AP did MRgFUS technical development and performed all MRgFUS renal denervation procedures. EK configured and monitored all MRI pulse sequences. JRH and EM designed, built and maintained the MRI RF coils. MS did all pathological review and analysis. JS, NM and AP designed the study. AP analyzed all MRI data. JS and AP drafted the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
This study was conducted with Institutional Animal Care and Use Committee approval under Good Laboratory Practices standards.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.View ArticlePubMedGoogle Scholar
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.View ArticlePubMedGoogle Scholar
- Fergus IV. Antihypertensive pharmacotherapy: adverse effects of medications promote nonadherence. J Cardiometab Syndr. 2009;4(1):E1–3.View ArticlePubMedGoogle Scholar
- Erdine S, Arslan E. Patient adherence in the treatment of hypertension: the role of combination therapies. Future Cardiol. 2010;6(4):437–40.View ArticlePubMedGoogle Scholar
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19.View ArticlePubMedGoogle Scholar
- Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–82.PubMedGoogle Scholar
- DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002;11(2):197–200.View ArticlePubMedGoogle Scholar
- DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75–197.PubMedGoogle Scholar
- DiBona GF. Sympathetic neural control of the kidney in hypertension. Hypertension. 1992;19(1 Suppl):I28–35.View ArticlePubMedGoogle Scholar
- Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1(6757):403–8.View ArticlePubMedGoogle Scholar
- DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245–53.View ArticlePubMedGoogle Scholar
- Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension: One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial. Circulation. 2012;126(25):2976–82.View ArticlePubMedGoogle Scholar
- Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9.View ArticlePubMedGoogle Scholar
- Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9.View ArticlePubMedGoogle Scholar
- Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940–6.View ArticlePubMedGoogle Scholar
- Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–70.View ArticlePubMedGoogle Scholar
- Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.View ArticlePubMedGoogle Scholar
- Mahfoud F, Luscher TF. Renal denervation: symply trapped by complexity? Eur Heart J. 2015;36(4):199–202.View ArticlePubMedGoogle Scholar
- Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27.View ArticlePubMedGoogle Scholar
- Wang Q, Guo R, Rong S, Yang G, Zhu Q, Jiang Y, Deng C, Liu D, Zhou Q, Wu Q, et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. J Am Coll Cardiol. 2013;61(21):2185–92.View ArticlePubMedGoogle Scholar
- Neuzil P, Ormiston J, Brinton TJ, Starek Z, Esler M, Dawood O, Anderson TL, Gertner M, Whitbourne R, Schmieder RE. Externally Delivered Focused Ultrasound for Renal Denervation. JACC Cardiovascular interventions. 2016;9(12):1292–9. doi:https://doi.org/10.1016/j.jcin.2016.04.013. PubMed PMID: 27339848.View ArticlePubMedGoogle Scholar
- Neuzil P, Whitbourn R, Starek Z, Esler M, Brinton T, Gertner M. TCT-61 Optimized external focused ultrasound for renal sympathetic denervation - Wave II trial. J Am Coll Cardiol. 2013;62(18):B20.View ArticleGoogle Scholar
- Koopmann M, Shea J, Kholmovski E, de Bever J, Minalga E, Holbrook M, Merrill R, Hadley JR, Owan T, Salama ME, et al. Renal sympathetic denervation using MR-guided high-intensity focused ultrasound in a porcine model. J Ther Ultrasound. 2016;4:3.View ArticlePubMedPubMed CentralGoogle Scholar
- Freyhardt P, Heckmann L, Beck A, Stolzenburg N, Schnorr J, Kamp J, Rinnenthal JL, Hamm B, Gunther RW, Streitparth F. MR-guided high-focused ultrasound for renal sympathetic denervation-a feasibility study in pigs. J Ther Ultrasound. 2014;2:12.View ArticlePubMedPubMed CentralGoogle Scholar
- Winternitz SR, Katholi RE, Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J Clin Invest. 1980;66(5):971–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1):141–6.View ArticlePubMedGoogle Scholar
- Kellman P, Aletras AH, Mancini C, McVeigh ER, Arai AE. T2-prepared SSFP improves diagnostic confidence in edema imaging in acute myocardial infarction compared to turbo spin echo. Magn Reson Med. 2007;57(5):891–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Maruvada S, Harris GR, Herman BA, King RL. Acoustic power calibration of high-intensity focused ultrasound transducers using a radiation force technique. J Acoust Soc Am. 2007;121(3):1434–9.View ArticlePubMedGoogle Scholar
- Shea JE, Garlick JW, Salama ME, Mendenhall SD, Moran LA, Agarwal JP. Side-to-side nerve bridges reduce muscle atrophy after peripheral nerve injury in a rodent model. J Surg Res. 2014;187(1):350–8.View ArticlePubMedGoogle Scholar
- Duck FA. Physical properties of tissues: a comprehensive reference book. London, New York, San Francisco: Academic Press; 2013.Google Scholar
- Roberts A. Magnetic resonance-guided focused ultrasound for uterine fibroids. Semin Interv Radiol. 2008;25(4):394–405.View ArticleGoogle Scholar
- Yoon SW, Lee C, Cha SH, Yu JS, Na YJ, Kim KA, Jung SG, Kim SJ. Patient selection guidelines in MR-guided focused ultrasound surgery of uterine fibroids: a pictorial guide to relevant findings in screening pelvic MRI. Eur Radiol. 2008;18(12):2997–3006.View ArticlePubMedGoogle Scholar
- Kyriakou A, Neufeld E, Werner B, Paulides MM, Szekely G, Kuster N. A review of numerical and experimental compensation techniques for skull-induced phase aberrations in transcranial focused ultrasound. Int J Hyperth. 2014;30(1):36–46.View ArticleGoogle Scholar
- Mougenot C, Tillander M, Koskela J, Kohler MO, Moonen C, Ries M. High intensity focused ultrasound with large aperture transducers: a MRI based focal point correction for tissue heterogeneity. Med Phys. 2012;39(4):1936–45.View ArticlePubMedGoogle Scholar
- Farrer AI, Almquist S, Dillon CR, Neumayer LA, Parker DL, Christensen DA, Payne A. Phase aberration simulation study of MRgFUS breast treatments. Med Phys. 2016;43(3):1374.View ArticlePubMedPubMed CentralGoogle Scholar